A Phase 2/3 interventional study of Galunisertib and Placebo in Myelodysplastic Syndromes, sponsored by Eli Lilly and Company. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Myelodysplastic Syndromes with a site in Germany — 16 open to participants now, 31 under way, 13 of them phase 3. Myelodysplastic Syndromes · Germany.
Among the 160 studies in Myelodysplastic Syndromes with a site in Germany, this one is the 103rd largest by enrollment of the 143 interventional ones that give a count, is one of 13 that started in 2014, is one of 5 in phase 2/3, and was the 68th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →16 of the 160 studies in Myelodysplastic Syndromes with a site in Germany are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany
Ages 18+
Takeda · Sites in Germany, United States, Argentina and 25 more countries
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 6 more countries
Ages 16+
GlaxoSmithKline · Sites in Germany, United States, Canada and 6 more countries
Ages 18+
Swedish Orphan Biovitrum · Sites in Germany, United States, Canada and 5 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 78 · Phase 3 48 · Phase 4 1
First in 1995; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 87 across the 143 interventional studies, 189 across the 16 observational. Of the 113 that completed or were terminated, 49 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
106 of 160 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
7 of the studies in Myelodysplastic Syndromes with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04401748Phase 3AbbVieStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | 2027-07 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT04232241Universitätsklinikum Hamburg-EppendorfMatched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | 2026-11-22 |
| NCT06782373Swedish Orphan BiovitrumA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 160 studies in Myelodysplastic Syndromes with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of the study drug known as galunisertib in participants with myelodysplastic syndromes (MDS). Participants with different degrees of disease (very low, low, and intermediate risk) will be studied. The study treatment is expected to last about 6 months for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
Drug: Galunisertib
Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
Drug: Placebo
150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
Drug: Galunisertib
Administered orally
Also known as: LY2157299
Administered orally
Percentage of Participants With Hematological Improvement (HI)
Percentage of participants with hematological improvement (HI) based on International Working Group (IWG) 2006 criteria in participants with very low, low, and intermediate-risk myelodysplastic syndromes treated with Galunisertib plus best supportive care, as assessed by the International Prognostic Scoring System (IPSS-R). To be classified as an HI responder, the HI response must have lasted at least 8 weeks (56 days).
Time frame: Baseline through end of study treatment (24 weeks)
Percentage of Participants Who Are Transfusion-free or Have Hemoglobin (Hb) Increase ≥1.5 Grams/Deciliter Maintained for 8 Weeks During Phase 3
Comparison of the percentage of participants with very low-, low-,and intermediate-risk MDS who were transfusion-free or had an increase ≥1.5 g/dL in hemoglobin (Hb) maintained for at least 8 weeks within the first 24 weeks of treatment with galunisertib plus best supportive care or placebo plus best supportive care and assessed by IPSS-R. The Phase 3 portion of this study was not conducted because efficacy level required in phase 2 to move forward to phase 3 was not achieved.
Time frame: Baseline through end of study treatment (24 weeks)
Change From Baseline in Brief Fatigue Inventory (BFI)
The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity of fatigue is assessed using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine.
Time frame: Baseline, Follow up (final visit up to 24 months)
Change From Baseline in EuroQol 5-Dimension 5 Level Instrument
EuroQol 5-Dimension 5 Level Instrument (EQ-5D-5L) was not conducted, trial terminated prior to Phase 3. No data collected.
Time frame: Phase 3: Baseline, Cycle 2, Cycle 4, Cycle 6 (Cycle = 28 days)
Percentage of Participants With Cytogenetic Response
Percentage of Participants with Cytogenetic Response with either complete or partial response. Complete cytogenetic response is the disappearance of the chromosomal abnormality without appearance of new ones. Partial cytogenetic response is at least 50% reduction of the chromosomal abnormality.
Time frame: Baseline through end of study treatment (24 weeks)
Percentage of Participants Who Are Hospitalized (Resource Utilization)
Percentage of any participant with a hospitalization admission and discharge date on the same day are counted as a half-day in the duration of hospitalization.
Time frame: Baseline through end of study treatment (24 weeks)
Population Pharmacokinetics (PK): Mean Population Clearance of Galunisertib
Population mean (between-participant coefficient variation \[CV%\]) apparent clearance.
Time frame: Day 1 pre-dose & between 0.5 to 2 hours post dose; Day 14 pre-dose, between 0.5 to 2 & between 3 to 5 hours post dose; Days 15 & 16 (if logistically possible) between 0.5 to 2 hours post dose
Overall Survival (OS)
Overall survival is defined as the time from the date of first dose to the date of death from any cause.
Time frame: Baseline to date of death from any cause (Up to 2 years)
Number of Participants With a Change in Bone Marrow Fibrosis Grading
Change from baseline in bone marrow fibrosis measured the number of participants with a change in bone marrow fibrosis grading (negative, mild, moderate, and severe).
Time frame: Baseline, Cycle 6 (Cycle = 28 days)
| Milestone | Galunisertib at 150 mg | Galunisertib at 80 mg |
|---|---|---|
| Started | 41 | 2 |
| Received at least 1 dose of study drug | 41 | 2 |
| Completed | 29 | 1 |
| Not completed | 12 | 1 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Progressive disease | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 |
Percentage of participants with hematological improvement (HI) based on International Working Group (IWG) 2006 criteria in participants with very low, low, and intermediate-risk myelodysplastic syndromes treated with Galunisertib plus best supportive care, as assessed by the International Prognostic Scoring System (IPSS-R). To be classified as an HI responder, the HI response must have lasted at least 8 weeks (56 days).
| percentage of participants | Galunisertib at 150 mg | Arm: Galunisertib at 80 mg |
|---|---|---|
| Percentage of Participants With Hematological Improvement (HI) | 31.7 (18.1 to 48.1) | 0.0 (0.0 to 84.2) |
Comparison of the percentage of participants with very low-, low-,and intermediate-risk MDS who were transfusion-free or had an increase ≥1.5 g/dL in hemoglobin (Hb) maintained for at least 8 weeks within the first 24 weeks of treatment with galunisertib plus best supportive care or placebo plus best supportive care and assessed by IPSS-R. The Phase 3 portion of this study was not conducted because efficacy level required in phase 2 to move forward to phase 3 was not achieved.
No measurements were reported for this outcome.
The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. The severity of fatigue is assessed using an 11-point numeric scale, with 0 = no fatigue and 10 = fatigue as bad as you can imagine.
| units on a scale | Galunisertib at 150 mg | Galunisertib at 80 mg |
|---|---|---|
| Current Fatigue at Follow-up | 0.818 ± 0.42 | -1.005 ± 2.08 |
| Usual Fatigue at Follow-up | -0.017 ± 0.37 | -0.157 ± 1.87 |
| Worst Fatigue at Follow-up | -0.191 ± 0.38 | -0.063 ± 1.93 |
EuroQol 5-Dimension 5 Level Instrument (EQ-5D-5L) was not conducted, trial terminated prior to Phase 3. No data collected.
No measurements were reported for this outcome.
Percentage of Participants with Cytogenetic Response with either complete or partial response. Complete cytogenetic response is the disappearance of the chromosomal abnormality without appearance of new ones. Partial cytogenetic response is at least 50% reduction of the chromosomal abnormality.
| percentage of participants | Galunisertib at 150 mg | Galunisertib at 80 mg |
|---|---|---|
| Percentage of Participants With Cytogenetic Response | 2.4 (0.1 to 12.9) | 0 (0 to 0) |
Percentage of any participant with a hospitalization admission and discharge date on the same day are counted as a half-day in the duration of hospitalization.
| percentage of participants | Galunisertib at 150 mg | Galunisertib at 80 mg |
|---|---|---|
| Percentage of Participants Who Are Hospitalized (Resource Utilization) | 24.3 | 0 |
Population mean (between-participant coefficient variation \[CV%\]) apparent clearance.
| Liter per hour (L/h) | Galunisertib |
|---|---|
| Population Pharmacokinetics (PK): Mean Population Clearance of Galunisertib | 32 ± 52 |
Overall survival is defined as the time from the date of first dose to the date of death from any cause.
| days | Galunisertib at 150 mg |
|---|---|
| Overall Survival (OS) | 679 (29 to 729) |
Change from baseline in bone marrow fibrosis measured the number of participants with a change in bone marrow fibrosis grading (negative, mild, moderate, and severe).
| participants | Galunisertib at 150 mg |
|---|---|
| Number of Participants With a Change in Bone Marrow Fibrosis Grading | 11 |
Collected over Baseline through end of study treatment or death from any cause (Up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Galunisertib at 150 mg | — | 8/41 (19.5%) | 33/41 (80.5%) |
| Galunisertib at 80 mg | — | 0/2 (0%) | 2/2 (100%) |
| Event | Galunisertib at 150 mg | Galunisertib at 80 mg |
|---|---|---|
| Cardiac failureCardiac disorders | 2/41 | 0/2 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/41 | 0/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/41 | 0/2 |
| LymphadenopathyBlood and lymphatic system disorders | 1/41 | 0/2 |
| Crohn's diseaseGastrointestinal disorders | 1/41 | 0/2 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 1/41 | 0/2 |
| PneumoniaInfections and infestations | 1/41 | 0/2 |
| Respiratory syncytial virus infectionInfections and infestations | 1/41 | 0/2 |
| Tongue abscessInfections and infestations | 1/41 | 0/2 |
| Event | Galunisertib at 150 mg | Galunisertib at 80 mg |
|---|---|---|
| AstheniaGeneral disorders | 5/41 | 1/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/41 | 1/2 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/41 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 7/41 | 0/2 |
| VomitingGastrointestinal disorders | 5/41 | 0/2 |
| PyrexiaGeneral disorders | 5/41 | 0/2 |
| FatigueGeneral disorders | 4/41 | 0/2 |
| NasopharyngitisInfections and infestations | 4/41 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 3/41 | 0/2 |
| NauseaGastrointestinal disorders | 3/41 | 0/2 |
All participants (including the Galunisertib at 80 mg exploratory arm) who received at least one dose of study drug.
| Age, Continuous(years) | Galunisertib at 150 mg | Galunisertib at 80 mg | Total |
|---|---|---|---|
| Mean | 70.49 ± 7.65 | 62.50 ± 10.61 | 70.12 ± 7.83 |
| Sex: Female, Male(Participants) | Galunisertib at 150 mg | Galunisertib at 80 mg | Total |
|---|---|---|---|
| Female | 15 | 1 | 16 |
| Male | 26 | 1 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Galunisertib at 150 mg | Galunisertib at 80 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 0 | 5 |
| Not Hispanic or Latino | 32 | 2 | 34 |
| Unknown or Not Reported | 4 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Galunisertib at 150 mg | Galunisertib at 80 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 41 | 2 | 43 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Galunisertib at 150 mg | Galunisertib at 80 mg | Total |
|---|---|---|---|
| Italy | 8 | 0 | 8 |
| Germany | 23 | 0 | 23 |
| Spain | 10 | 2 | 12 |
| IPSS-R Prognostic Risk Score(Participants) | Galunisertib at 150 mg | Galunisertib at 80 mg | Total |
|---|---|---|---|
| Very Low= (≤1.5) | 2 | 0 | 2 |
| Low= (>1.5 - 3) | 30 | 1 | 31 |
| Intermediate= (>3 - 4.5) | 9 | 1 | 10 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Mar 2014, a primary completion of Mar 2016 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 3 years after primary completion. A results delay was requested in Aug 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY-2157299